comparemela.com

Latest Breaking News On - Company us securities - Page 1 : comparemela.com

ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K

ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Cayman-islands
Delaware
United-states
Bankura
Ankara
Turkey
Washington
Singapore
American
Kiran-kumar-asarpota
Company-annual-report-on-form
Pharmaceuticals-pte

Volaris Reports Financial Results for the First Quarter

MEXICO CITY, April 22, 2024 (GLOBE NEWSWIRE) Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the.

Israel
Mexico-city
Distrito-federal
Mexico
United-states
America
Mexican
Ricardo-mart
Enrique-beltranena
Company-us-securities
International-financial-reporting-standards
Pratt-whitney

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mexico-city
Distrito-federal
Mexico
United-states
America
Mexican
Contactricardo-mart
Enrique-beltranena
Us-securities-exchange
Pratt-whitney
Company-us-securities
Exchange-commission

Controladora Vuela Compañía de Aviación B de C : Volaris Reports Financial Results for the First Quarter 2024

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million Mexico City, Mexico, April 22, 2024 -.

United-states
Israel
Mexico-city
Distrito-federal
Mexico
Mexican
America
Enrique-beltranena
Ricardo-mart
International-financial-reporting-standards
Pratt-whitney
Us-securities-exchange

ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K

ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Interim readout.

California
United-states
Singapore
America
Carl-firth
Emma-thompson
Ashleyr-robinson
Company-us-securities
Spurwing-communications
Linkedin
Pharmaceuticals-nasdaq
Company-annual-report-on-form

vimarsana © 2020. All Rights Reserved.